AU2015258174A1 - Antimicrobial polymer compositions and the use thereof - Google Patents
Antimicrobial polymer compositions and the use thereof Download PDFInfo
- Publication number
- AU2015258174A1 AU2015258174A1 AU2015258174A AU2015258174A AU2015258174A1 AU 2015258174 A1 AU2015258174 A1 AU 2015258174A1 AU 2015258174 A AU2015258174 A AU 2015258174A AU 2015258174 A AU2015258174 A AU 2015258174A AU 2015258174 A1 AU2015258174 A1 AU 2015258174A1
- Authority
- AU
- Australia
- Prior art keywords
- antimicrobial
- anionic
- acid
- metal
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 229920002118 antimicrobial polymer Polymers 0.000 title description 2
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 118
- 229920000728 polyester Polymers 0.000 claims abstract description 94
- 125000000129 anionic group Chemical group 0.000 claims abstract description 92
- 229910052751 metal Inorganic materials 0.000 claims abstract description 82
- 239000002184 metal Substances 0.000 claims abstract description 82
- 239000004599 antimicrobial Substances 0.000 claims abstract description 29
- 238000005342 ion exchange Methods 0.000 claims abstract description 15
- 239000003999 initiator Substances 0.000 claims description 44
- 229910052709 silver Inorganic materials 0.000 claims description 42
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 37
- -1 aliphatic lactone Chemical class 0.000 claims description 33
- 239000004332 silver Substances 0.000 claims description 33
- 239000000178 monomer Substances 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 13
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 11
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 10
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 9
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 6
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 125000002524 organometallic group Chemical group 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- JJTUDXZGHPGLLC-ZXZARUISSA-N (3r,6s)-3,6-dimethyl-1,4-dioxane-2,5-dione Chemical compound C[C@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-ZXZARUISSA-N 0.000 claims description 5
- SJDLIJNQXLJBBE-UHFFFAOYSA-N 1,4-dioxepan-2-one Chemical compound O=C1COCCCO1 SJDLIJNQXLJBBE-UHFFFAOYSA-N 0.000 claims description 5
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 claims description 5
- ULKFLOVGORAZDI-UHFFFAOYSA-N 3,3-dimethyloxetan-2-one Chemical compound CC1(C)COC1=O ULKFLOVGORAZDI-UHFFFAOYSA-N 0.000 claims description 5
- MVXNGTMKSZHHCO-UHFFFAOYSA-N 3-methyl-1,4-dioxane-2,5-dione Chemical compound CC1OC(=O)COC1=O MVXNGTMKSZHHCO-UHFFFAOYSA-N 0.000 claims description 5
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 5
- YKVIWISPFDZYOW-UHFFFAOYSA-N 6-Decanolide Chemical compound CCCCC1CCCCC(=O)O1 YKVIWISPFDZYOW-UHFFFAOYSA-N 0.000 claims description 5
- 229930182843 D-Lactic acid Natural products 0.000 claims description 5
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims description 5
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 5
- 150000001280 alpha hydroxy acids Chemical group 0.000 claims description 5
- 229910052787 antimony Inorganic materials 0.000 claims description 5
- 229910052797 bismuth Inorganic materials 0.000 claims description 5
- 229940022769 d- lactic acid Drugs 0.000 claims description 5
- 229960004275 glycolic acid Drugs 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 229910052741 iridium Inorganic materials 0.000 claims description 5
- 229960000448 lactic acid Drugs 0.000 claims description 5
- 150000002596 lactones Chemical class 0.000 claims description 5
- 229910052748 manganese Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- JMRZMIFDYMSZCB-UHFFFAOYSA-N morpholine-2,5-dione Chemical compound O=C1COC(=O)CN1 JMRZMIFDYMSZCB-UHFFFAOYSA-N 0.000 claims description 5
- 229910052759 nickel Inorganic materials 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 229910052718 tin Inorganic materials 0.000 claims description 5
- ZNLAHAOCFKBYRH-UHFFFAOYSA-N 1,4-dioxane-2,3-dione Chemical compound O=C1OCCOC1=O ZNLAHAOCFKBYRH-UHFFFAOYSA-N 0.000 claims description 4
- QMDUQRDPJXKZAO-UHFFFAOYSA-N 3,3-diethyl-1,4-dioxane-2,5-dione Chemical compound CCC1(CC)OC(=O)COC1=O QMDUQRDPJXKZAO-UHFFFAOYSA-N 0.000 claims description 4
- 229930188620 butyrolactone Natural products 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 150000001261 hydroxy acids Chemical class 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000003106 tissue adhesive Substances 0.000 claims description 2
- FQFQWTFNRFUWKM-UHFFFAOYSA-N 3,3-diethyloxetan-2-one Chemical compound CCC1(CC)COC1=O FQFQWTFNRFUWKM-UHFFFAOYSA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 238000000576 coating method Methods 0.000 description 32
- 239000011248 coating agent Substances 0.000 description 28
- 150000003839 salts Chemical class 0.000 description 27
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000758 substrate Substances 0.000 description 12
- 229910021645 metal ion Inorganic materials 0.000 description 9
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 9
- 229920006318 anionic polymer Polymers 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 150000003378 silver Chemical class 0.000 description 8
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 8
- 229940071536 silver acetate Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 150000002500 ions Chemical group 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004070 electrodeposition Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229940100890 silver compound Drugs 0.000 description 2
- 150000003379 silver compounds Chemical class 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
- SMYHOXRBWMCEBS-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;silver Chemical compound [Ag].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O SMYHOXRBWMCEBS-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229910001316 Ag alloy Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NBYLLBXLDOPANK-UHFFFAOYSA-M silver 2-carboxyphenolate hydrate Chemical compound C1=CC=C(C(=C1)C(=O)O)[O-].O.[Ag+] NBYLLBXLDOPANK-UHFFFAOYSA-M 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 229960001516 silver nitrate Drugs 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- TYTYIUANSACAEM-UHFFFAOYSA-M silver;2,4,6-trinitrophenolate Chemical compound [Ag+].[O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O TYTYIUANSACAEM-UHFFFAOYSA-M 0.000 description 1
- TYIRIQHLESJHCJ-UHFFFAOYSA-M silver;2-acetyloxybenzoate Chemical compound [Ag+].CC(=O)OC1=CC=CC=C1C([O-])=O TYIRIQHLESJHCJ-UHFFFAOYSA-M 0.000 description 1
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
- MNMYRUHURLPFQW-UHFFFAOYSA-M silver;dodecanoate Chemical compound [Ag+].CCCCCCCCCCCC([O-])=O MNMYRUHURLPFQW-UHFFFAOYSA-M 0.000 description 1
- ORYURPRSXLUCSS-UHFFFAOYSA-M silver;octadecanoate Chemical compound [Ag+].CCCCCCCCCCCCCCCCCC([O-])=O ORYURPRSXLUCSS-UHFFFAOYSA-M 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
An antimicrobial composition comprising an ionic complex of an anionic polyester with an antimicrobial metal, wherein the anionic polyester has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g. Document2
Description
1 ANTIMICROBIAL POLYMER COMPOSITIONS AND THE USE THEREOF This application is a continuation-in-part of and claims benefit under 35 5 U.S.C. §120 to copending application U.S. Serial No. 11/132,992, filed May 19, 2005, which is incorporated by reference herein in its entirety. FIELD OF THE INVENTION The present invention relates generally to polymer compositions and their 10 use for making or coating articles, such as medical devices. More specifically the invention relates to antimicrobial compositions that are complexes of an anionic polymer with an antimicrobial metal. Further, the present invention relates to complexes of anionic polyester with silver, which may be used alone or in combination with medical devices. The present invention also 15 relates to medical devices utilizing such antimicrobial compositions. BACKGROUND OF THE INVENTION Whenever a medical device is used in a surgical setting, a risk of infection is created. The risk of infection dramatically increases for invasive or 20 implantable medical devices, such as intravenous catheters, arterial grafts, intrathecal or intracerebral shunts and prosthetic devices, which create a portal of entry for pathogens while in intimate contact with body tissues and fluids. The occurrence of surgical site infections is often associated with bacteria that colonize on the medical device. For example, during a surgical 25 procedure, bacteria from the surrounding atmosphere may enter the surgical site and attach to the medical device. Bacteria can use the implanted medical device as a pathway to surrounding tissue. Such bacterial colonization on the medical device may lead to infection and morbidity and mortality to the patient. 30 Document2 2 A number of methods for reducing the risk of infection associated with invasive or implantable medical devices have been developed that incorporate antimicrobial metals or metal salts into the medical devices. Such devices desirably provide effective levels of the antimicrobial metal while the 5 device is being used. For many years silver and silver salts have been used as antimicrobial agents in medical applications. Such medical applications include the use of aqueous silver nitrate solutions to prevent eye infection in newborn babies. 10 Silver salts have also been used to prevent and control infection such as conjunctivitis, urethritis, and vaginitis. Additionally, silver and silver salts have been used as antimicrobial agents in conjunction with medical devices, such as catheters, cannulae, and stents. 15 Typically, the silver or silver salt is deposited directly onto the surface of the medical device via conventional coating techniques, such as vapor coating, sputter coating, or ion beam coating. For example, WO 2004054503A2 and U.S. Patent No. 6,878,757 to Roby 20 describe antimicrobial coatings applicable to sutures where the coating comprises (i) mixtures of caprolactone copolymers and silver stearate, and (ii) mixtures of copolymers of epsilon-caprolactone, bioabsorbable monomer and sodium stearoyl lactylate or the silver salt of stearoyl lactylate, respectively. The silver salt in both of these references remains in a salt form 25 in the copolymer matrix, and silver ions are released into a target environment from the coating by solubilization of the silver salt in the target environment. In turn, the solubility of the silver salt is a function of the nature of environment where it is delivered, and factors such as counter-ion concentration and ionic strength of the target environment. 30 Document2 3 U.S. Patent No. 6,881,766 to Hain describes sutures fabricated from and/or coated with compositions including water-soluble glass. The water-soluble glass optionally includes a therapeutic agent, e.g., silver, to promote wound repair. The silver in this case may be incorporated in the form of an 5 inorganic silver salt such as silver oxide, silver nitrate or silver orthophosphate. Similar to the reference described above, the release of the silver ions into the target environment may be dependent upon the solubility of the silver salt in the target environment. 10 Other metals, such as zinc, copper, magnesium and cerium, have also been found to possess antimicrobial properties, both alone and in combination with silver, some of which exhibited synergistic benefits of their combinations. These and other metals have been shown to provide antimicrobial behavior even in minute quantities. 15 Other methods of coating antimicrobial metals or metal salts onto a substrate involve deposition or electro-deposition of the metal or metal salt from solution. Additional techniques for incorporating metal into a medical device include dipping, spraying or brushing a liquid solution of the metal or metal 20 salt onto a polymer, for example, in pellet form, prior to processing the medical device. Alternatively, a solid form of the metal or metal salt can be mixed with a finely divided or liquefied polymeric resin, which is then molded into the article. Also, the metal or metal salt can be mixed with monomers of the material prior to polymerization. 25 However, problems associated with medical devices having metal or metal salts deposited thereon by conventional incorporation techniques include poor adhesion of the metal or metal salt on the medical device, and lack of uniformity in the concentration of the metal or metal salt throughout the 30 coating. Also, it is believed that deposition or electro-deposition of the antimicrobial metal onto a medical device produces coatings that do not Document2 4 release the metal from the coating easily, and therefore require direct contact with microbes in the tissue to have an antimicrobial effect. U.S. Patent No. 6,153,210 to Roberts et al. discloses polymeric 5 microparticles containing metal ions, preferably silver ions, for control of periodontal disease. The microparticles can be made from poly(lactide-co glycolide) (PLGA) having MW of about 12,000 Daltons, with which the metal ions are mixed or complexed. However, Roberts et al. are silent as to the ion exchange capacity of their polymers, and as to PLGA having MW of less 10 than about 10,000 Daltons. Therefore, there is a need to provide an antimicrobial composition where the release mechanism of metal ions into the target environment is not dependent upon solubilization in the target environment. More particularly, 15 there is a need for an antimicrobial composition that exhibits immediate activity upon contact with fluids in the human body. Additionally, it is desirable to have an antimicrobial composition that adheres well to medical devices, as well as antimicrobial medical devices having a uniform distribution of metal or metal salts throughout. 20 SUMMARY OF THE INVENTION In one embodiment, the present application is directed to an antimicrobial composition comprising an ionic complex of an anionic polyester with an antimicrobial metal, wherein the anionic polyester has an ion exchange 25 capacity from about 0.19 meq/g to about 1.0 meq/g. In another embodiment, the antimicrobial composition has an anionic polyester having a weight average molecular weight (Mw) between about 2000 and about 7200 Daltons. 30 In another embodiment, the composition contains from about 20,000 ppm to about 96,000 ppm by weight of the antimicrobial metal. Document2 5 Conveniently, the anionic polyester is prepared from a ring-opening polymerization of aliphatic lactone monomers polymerized in the presence of an organometallic catalyst and an anionic initiator. 5 Preferably, the aliphatic lactone monomer is selected from the group consisting of glycolide, trimethylene carbonate, L-lactide, D-lactide, DL lactide, mesolactide, g-caprolactone, p-dioxanone, 1,3-dioxan-2-one, 5 valerolactone, p-butyrolactone, E-decalactone, 2,5-diketomorpholine, pivalolactone, a,a-diethylpropiolactone, ethylene carbonate, ethylene 10 oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, y butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl dioxepan-2-one, 6,8-dioxabicycloctane-7-one and combinations thereof. Advantageously, the anionic initiator is selected from the group consisting of 15 alpha-hydroxy acids, glycolic acid, D- lactic acid, DIL-lactic acid, L-lactic acid, p-hydroxyacids, y-hydroxyacids, 6-hydroxyacids, s-hydroxyacids, g hydroxycaproic acid, polyhydroxyacids, tartaric acid, citric acid and glucoronic acid, and is present at a mole ratio of lactone monomer to initiator between about 10 and 30. 20 Preferably, the mole ratio of lactone monomer to initiator is between about 10 and 25, and the antimicrobial metal is selected from the group consisting of Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, Zn, Ni, Mg, and Mn. More preferably, the antimicrobial metal is silver. 25 In another embodiment, the present application is directed to a medical device having an antimicrobial composition comprising: an ionic complex of an anionic polyester with an antimicrobial metal wherein the anionic polyester has an ion exchange capacity from about 0.19 meq/g to about 1.0 30 meq/g. Document2 6 Advantageously, the medical device is in the form of a fiber, mesh, powder, microspheres, flakes, sponge, foam, fabric, nonwoven, woven mat, a film, suture anchor device, suture, catheter, staple, surgical tack, clips, plate and screw, drug delivery device, adhesion prevention barrier, and tissue 5 adhesive. Preferably, the anionic polyester has a weight average molecular weight (Mw) between about 2000 and about 7200 Daltons. Conveniently, the composition contains from about 20,000 ppm to about 10 96,000 ppm by weight of the antimicrobial metal. In another embodiment, the present application is directed to a method of making an ionic complex of an anionic polyester with an antimicrobial metal comprising: conducting a ring-opening polymerization of one or more 15 aliphatic lactone monomers in the presence of an organometallic catalyst and an anionic initiator at a mole ratio of lactone monomer to initiator between about 10 and 30; recovering the anionic polyester which has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g; conducting an ion exchange between carboxylic acid groups on said anionic polyester and 20 said antimicrobial metal; and recovering said ionic complex of said anionic polyester and said antimicrobial metal. Preferably, the aliphatic lactone monomer is selected from the group consisting of glycolide, trimethylene carbonate, L-lactide, D-lactide, DL 25 lactide, mesolactide, g-caprolactone, p-dioxanone, 1,3-dioxan-2-one, 5 valerolactone, p-butyrolactone, E-decalactone, 2,5-diketomorpholine, pivalolactone, a,a-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1 ,4-dioxan-2,5-dione, y butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl 30 dioxepan-2-one, 6,8-dioxabicycloctane-7-one and combinations thereof. Document2 7 Advantageously, the anionic initiator is selected from the group consisting of alpha-hydroxy acids, glycolic acid, D-lactic acid, DL-lactic acid, L-lactic acid, p-hydroxyacids, y-hydroxyacids, 6-hydroxyacids, s-hydroxyacids, g hydroxycaproic acid, polyhydroxyacids, tartaric acid, citric acid and 5 glucoronic acid. Preferably, the antimicrobial metal is selected from the group consisting of Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, Zn, Ni, Mg, and Mn, and is more preferably silver. 10 In another embodiment, the ion exchange is conducted in a solution of said antimicrobial metal in an aqueous soluble alcohol selected from the group consisting of ethanol, n-propyl alcohol, and isopropyl alcohol. 15 DETAILED DESCRIPTION The present invention provides an antimicrobial composition comprising an ionic complex of an anionic polymer with an antimicrobial metal. In one embodiment, the antimicrobial composition comprises a complex of an anionic polyester with an antimicrobial metal, wherein the anionic polyester 20 molecules have at least one carboxylic acid group that may be linear or branched. The term "complex" as used herein refers to an intimate mixture at the molecular scale, with ionic or electrostatic bonding between the antimicrobial 25 metal ions and carboxylic acid groups of the anionic polymer. The complex preferably comprises a salt formed between the anionic polymer and metal ions. The anionic polyester may be absorbable or nonabsorbable, and can be 30 synthesized via ring opening polymerization of aliphatic lactone monomers. Specifically, the aliphatic lactone monomers are polymerized in the presence of an organometallic catalyst and an initiator. The ring-opening Document2 8 polymerization process is well-known in the art, as described in more detail in U.S. Patent No. 4,289,873 to Kubo et al., the content of which is incorporated by reference as if set forth in its entirety. 5 Typical aliphatic lactone monomers that may be utilized to synthesize the anionic polyester described herein, and from which the repeating units of the anionic polyester are derived, are selected from the group consisting of glycolide, trimethylene carbonate, L-lactide, D-lactide, DL-lactide, mesolactide, E-caprolactone, p-dioxanone, 1,3-dioxan-2-one, 6 10 valerolactone, p-butyrolactone, E-decalactone, 2,5-diketomorpholine, pivalolactone, a,a-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, y butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl dioxepan-2-one, 6,8-dioxabicycloctane-7-one and combinations thereof. 15 The organometallic catalysts include titanates and zirconates, and preferably organotin compounds such as stannous chloride and stannous octoate. The initiators are compounds containing at least one carboxylic acid group, 20 and at least one other reactive group such as an hydroxyl group or an amine. Typical initiators, suitable for the synthesis of an anionic polyester having carboxylic acid groups, are alpha-hydroxy acids such as glycolic acid, D lactic acid, DL-lactic acid, L-lactic acid, p-hydroxyacids, y-hydroxyacids, 6 hydroxyacids, and s-hydroxyacids such as g-hydroxycaproic acid. Preferable 25 initiators contain at least one carboxylic acid group and a primary hydroxyl group, such as glycolic acid. The alcohol group readily participates in a reaction that incorporates the initiator in the growing chain. Typical initiators suitable for the synthesis of branched polyesters with at least one carboxylic acid group are the polyhydroxyacids, such as glucoronic acid. 30 Document2 9 In certain embodiments, the anionic polyester may have only one carboxylic acid group per molecule. Such anionic polyesters are described in U.S. Patent Nos. 4,201,216 and 4,994,074, the entire content which is incorporated herein by reference 5 The anionic polyesters include homopolymers and copolymers of lactide and glycolide, i.e., polylactide, polyglycolide, and copolymers of lactide and glycolide with each other and with other reactive monomers; poly (p dioxanone); poly(alkylene oxalate); copolymers of vinyl acetates with 10 unsaturated carboxylic acids such as crotonic, acrylic and methacrylic acids; and mixtures of such polymers. Particularly preferred polymers are the copolymers of lactide and glycolide, which contain from about 15 to 85 % lactide, and have an inherent viscosity of from about 0.5 to 4.0 measured as a 0.1 percent solution in hexafluoroisopropanol at 250C. These polymers are 15 water-insoluble, rapidly absorbable, and soluble in many common organic solvents such as acetone, chloroform, toluene, xylene, and 1,1,2 trichloroethane. It is also possible to produce other anionic polyesters in a similar fashion with 20 terpolymers, tetramers, and the like, from building blocks including, but not limited to, glycolide, lactide, epsilon-caprolactone, trimethylene carbonate, and p-dioxanone. According to the present invention, anionic polyesters which are particularly 25 suitable for use in forming antimicrobial compositions can be formed in the ring-opening polymerization process by controlling the initiator ratio (IR). The term "initiator ratio" as used herein, refers to the total moles of monomer divided by the total moles of initiator. Generally, the lower the IR (i.e. the greater the amount of initiator relative to monomer), the lower the molecular 30 weight of the polymer so-formed. Document2 10 According to the present invention, the IR is preferably between about 10 to 30, or even between about 10 to 25, or even between about 10 to 15, which results in anionic polyesters having weight average molecular weights (Mw) of less than about 10,000 Daltons, preferably less than about 5,000 Daltons. 5 An anionic polyester which is a copolymer of epsilon-caprolactone and glycolide can be formed by using glycolic acid as an initiator and stannous octoate as the catalyst. The polymerization may be conducted in a batch process that allows the formation of a random copolymer. However, it is also 10 possible to conduct the polymerization in such a way as to allow for the formation of a semi-block copolymer. The initiator ratio may be varied to allow one to obtain a molecular weight that makes the final copolymer in a useable form. For example, the initiator ratio may range from about 5 to about 600, corresponding to a number average molecular weight (Mn) of 15 about 575 to about 43,000, respectively. When the anionic polyester is used to prepare a coating on a substrate such as a medical device, the initiator ratio may range from about 10 to 30, corresponding to a Mn of about 1,150 to about 3,450, respectively. The molecular weight of the copolymer can vary greatly depending on its ultimate application. 20 An anionic polyester which is a poly-(epsilon-caprolactone) that is polymerized with glycolic acid as an initiator, and is consequently terminated with a carboxylic acid group can be formed. For example, the initiator ratio may range from about 5 to about 600, corresponding to a Mn of about 575 to 25 about 34,000, respectively. When the anionic polyester is used to prepare a coating on a substrate such as a medical device, the initiator ratio ranges from about 10 to about 30, corresponding to a Mn of about 1,150 to about 3,450, respectively. 30 Document2 11 An anionic polyester which is a copolymer formed from lactide and glycolide with glycolic acid as an initiator can be formed. The initiator ratio ranges from about 10 to about 200, which corresponds to a Mn of about 1,170 to about 22,000, respectively. 5 Where the number of carboxylic acid groups is desirably 2 or more, one can provide an initiator that will cause the anionic polyester to form, for example, a branched structure. Examples of such initiators include, but are not limited to, tartaric acid, citric acid and the like. The branched structure may have 10 one or more carboxylic acid groups in one or more branches on the polymer backbone or side chain. They may even be in the form of a dendrimer or star structure. Advantageously, the anionic polyesters of the present invention have 15 unusually high ion exchange capacities (IEC), such as from about 0.19 meq/g to about 1.0 meq/g, preferably from about 0.24 to about 0.8 meq/g, or even from about 0.3 to about 0.8 meq/g, the higher the IEC, the greater the amount of antimicrobial metal which can be exchanged for the hydrogen atom of the free carboxylic acid groups of the polymer chains. 20 For example, the presently disclosed anionic polyesters can form antimicrobial compositions having from about 20,000 ppm to about 96,000 ppm, preferably from about 25,000 ppm to about 85,000 ppm, or even from about 30,000 ppm to about 85,000 ppm by weight (based on the composition 25 as a whole) of antimicrobial metal. The high IEC of the presently disclosed polymers is due in part to the relatively low molecular weights of the polymer chains, each of which is terminated by at least one free carboxylic acid group. Thus, on a per-unit 30 weight basis, the anionic polyesters of the present invention have many more free carboxylic acid sites for ion exchange than do similar polymers of higher molecular weight. Document2 12 The anionic polyesters formed by the presently disclosed process have weight average molecular weights (Mw) below about 10,000 Daltons, preferably below about 5,000 Daltons, or between about 1,000 to about 8,000 Daltons, or even between about 2,000 to about 7,200 Daltons. 5 Assuming a normal molecular weight distribution, the Mw is about twice the number average molecular weight (Mn) of these anionic polyesters. The IEC of the presently disclosed anionic polyesters is further enhanced by the selection of the above-disclosed anionic initiators, which have carboxylic 10 acid groups on one end thereof, and at least one other reactive group, such as amine or hydroxyl, such that the other reactive group is incorporated into the anionic polyester backbone and the carboxylic acid group of the initiator is available for ion exchange. 15 For comparison, the PLGA polyester disclosed in Example 1 of U.S. Patent No. 6,153,210 was examined. The PLGA is disclosed as being a 50:50 lactic:glycolic copolyester of MW 12,000, provided by Boehringer Ingelheim Chemicals as "RG502H". The specifications of RG502H are available at www resomer com, and indicate that the polyester has an acid number of 6 20 mg KOH/g. Back-calculations from this acid number reveal the following data for RG502H: IR = 72 Mn = 9354 Mw - 18,700 25 IEC = 0.107 meq/g Max ppm Ag = 11,403. Clearly the presently disclosed anionic polyesters have greatly increased IEC which permits much greater antimicrobial metal loadings and enhanced 30 antimicrobial activity as compared to RG502H. Document2 13 The antimicrobial metal ions (M) referred to herein are metal ions having antimicrobial efficacy, including but not limited to Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, Zn, Ni, Mg, and Mn. The source of the antimicrobial metal ion in the complex with the anionic polymer includes, but is not limited to, elemental 5 metals, metal compounds, alloys or mixtures thereof. Silver is especially potent as an antimicrobial metal against a broad spectrum of microorganisms. Preferably, the source of the antimicrobial metal in the complex with the anionic polymer is elemental silver, silver alloys, a silver 10 compound or mixtures thereof. The silver compound referred to herein is a compound comprising a silver ion, linked to another molecule via a covalent or non-covalent linkage. Examples of silver compounds include, but are not limited to, silver salts formed by silver ion with organic acids (e.g. acetic acids and fatty acids) or inorganic acids, such as silver sulfadiazine ("AgSD"), 15 silver oxide ("Ag 2 0"), silver carbonate ("Ag 2 CO3"), silver deoxycholate, silver salicylate, silver iodide, silver nitrate ("AgNO 3 "), silver paraaminobenzoate, silver paraaminosalicylate, silver acetylsalicylate, silver ethylenediaminetetraacetic acid ("Ag EDTA"), silver picrate, silver protein, silver citrate, silver lactate, silver acetate and silver laurate. 20 The complex of an anionic polyester and an antimicrobial metal may be made by treating an anionic polyester with a solution of the source of the antimicrobial metal. For example, the anionic polyester may be in the form of solid fibers, sheet, sponge or fabric. In certain embodiments, the anionic 25 polyester is an ion exchanger. In other embodiments, the anionic polyester may be in free acid form, in which case for example, the source of the antimicrobial metal may be a salt of a weak acid, whereby the anionic polyester is at least partially complexed by the metal salt. When using silver salts of weak acids, for example, the silver ion is exchanged for a proton on 30 the anionic polyester and part of the salt is converted to a weak acid. When silver salts are used in excess of the stoichiometric amount required by the anion exchanger, the mixture of weak acid and salt in the solution results in a Document2 14 buffered solution which maintains a fairly constant pH and controls the degree of exchange reaction. An equilibrium reaction is established whereby the silver ions are bound to the acid portion of the polyester and also to the salt molecules. The excess silver salts and the weak acid remain in solution, 5 while silver ions remain bound to the solid anionic polyester. The solid anonic polyester is then conveniently separated from the liquid/silver solution. Similar processes are described in EP-A-0437095, the entire content of which is expressly incorporated herein by reference. 10 The exchange reaction can be carried out in water or alcohol alone but is preferably carried out in mixtures of water and alcohols. The use of a mixture of water and alcohol provides good solubility for weak acid salts, and the alcohol enhances the ability of the anionic polyester to swell during the exchange reaction. Thus the physical properties (e.g. the inherent 15 mechanical strength) of the anionic polyester are retained. Isopropyl alcohol is the preferred alcohol because many of the above-mentioned silver salts have good solubility therein in combination with water. Preferably, the alcohol to water molar ratio is in the range of about 9:1 to 1:9. If the solution becomes too rich in alcohol, some salts may no longer be soluble particularly 20 if the alcohol is other than methanol. Linear and branched C2-C12 mono- or polyalcohols, including, but not limited to, n-propyl alcohol and ethanol, are suitable alcohols. The amount of metal salt used is generally about equal to or up to twice the 25 stoichiometric amount of carboxylic acid content of the polyester. Alternatively, a second charge of a stoichiometric amount of metal salt can be used if the reaction is recharged with fresh solvent and salt after the first charge reaches a constant pH. The material with elevated pH is then washed to remove the excess metal salt and ions therefrom. 30 Document2 15 The antimicrobial composition of the present invention provide the advantage of varying release kinetics for the antimicrobial metal ions. These varying release kinetics allow for an initial release of antimicrobial metal that provides antimicrobial activity immediately upon insertion in an aqueous environment, 5 followed by a continual, extended release of the antimicrobial metal from the composition, resulting in sustained antimicrobial activity over time for at least 12 days. In a further aspect, the antimicrobial composition may optionally contain 10 other components that improve the antimicrobial effectiveness of the composition, or that otherwise serve as active agents for other benefits. These components include, but are not limited to, additional antimicrobials, additional salts, any other excipients or active ingredients that provide the compositions with beneficial properties or enhance the antimicrobial activity 15 of the compositions. Such components include, but are not limited to, antimicrobial agents, antibiotics, and other active ingredients. The antimicrobial compositions described herein may be used to coat substrate materials. Additionally, they can be a part of the coating that 20 contains the antimicrobial composition described herein. These coatings may comprise either a single layer or multiple layers. In another embodiment, the antimicrobial composition may also be applied to a preformed article or part of an article of manufacture as a coating. The coated article may be produced, for example, by dipping the article into the composition, 25 coextruding the article, wire coating the article, or spraying the article with the composition and then drying the coated article. The antimicrobial composition may be made separately, and then applied as a coating to a substrate such as a medical device. Alternately, the 30 antimicrobial composition may be made in situ, for example, by first coating a substrate such as a medical device with the anionic polyester followed by in situ treatment with a solubilized salt of the antimicrobial metal, thus imparting Document2 16 antimicrobial properties to the substrate. Additionally, organic liquids such as organic solvents may be utilized to facilitate complexation of the antimicrobial metal and the anionic polyester. 5 The antimicrobial compositions described herein can be used alone or in combination with other polymer coatings to provide advantageous properties to the surface of the substrate. These compositions can also be used to deliver additional pharmaceutical agents that, for example, are antiinfective, anticoagulants, improve healing, are antiviral, antifungal, antithrombogenic or 10 impart other properties to coated substrates. The antimicrobial compositions can also be used to inhibit algae, fungal, mollusk, or microbial growth on surfaces. The antimicrobial compositions described herein may also be used as herbicides, insecticides, antifogging 15 agents, diagnostic agents, screening agents, and antifoulants. In another aspect, the present invention includes an article of manufacture that is a medical device that comprises the antimicrobial compositions described herein. In one embodiment, the antimicrobial composition can be 20 used to form an article or a portion of the article, for example by spinning, molding, casting, or extrusion. The antimicrobial composition can be utilized to manufacture a medical device including, but not limited to a fiber, mesh, powder, microspheres, 25 flakes, sponge, foam, fabric, nonwoven, woven mat, a film, suture anchor device, suture, staple, surgical tack, clips, plate and screw, drug delivery device, adhesion prevention barrier, and tissue adhesive. The medical device may be composed of one or more of the antimicrobial 30 compositions of the present invention, alone or in combination with other polymeric components. Document2 17 As discussed above, the antimicrobial metal may be complexed with the anionic polyester in an aqueous alcohol environment. In one embodiment, the antimicrobial metal may be incorporated into the anionic polyester prior to forming a substrate such as a medical device. In an alternative embodiment, 5 the antimicrobial metal can be incorporated into the anionic polyester after the formation of a substrate such as a medical device. For instance, the anionic polyester may be complexed with the antimicrobial metal by dipping, soaking, spraying or coating a medical device with the antimicrobial metal dispersed in an aqueous alcohol environment, as shown in Examples 1 to 3. 10 Example 1 An anionic polyester was prepared by the polymerization of epsilon caprolactone and glycolide, using glycolic acid as an initiator and a catalyst in the amounts given below: 15 epsilon-caprolactone 1.8208 moles glycolide 0.1789 moles glycolic acid 0.0666 moles (Initiator ratio 30) catalyst: Stannous octoate 0.33 molar in toluene 20 The anionic polyester was dissolved in ethyl acetate to make a 7% solids solution. Thereafter, a size 2/0 polyglactin 910 suture was immersion coated and air dried. The suture had 2.716 weight % coating. 25 In a bottle covered with aluminum foil, 201 grams of deionized water and 8 grams of isopropanol were mixed. Thereafter, 1.462 grams of silver acetate was added to the aqueous alcohol solution and mixed with a magnetic stirrer for 1% hours. 20 more grams of isopropyl alcohol was added and mixed to produce a silver salt solution. The size 2/0 coated polyglactin 910 suture 30 was immersed in a 50 gram aliquot of the silver salt solution at room temperature for 5 hours. The suture was rinsed by immersion in deionized water and vacuum dried at room temperature to produce a suture having the Document2 18 antimicrobial composition as a coating thereon. The amount of silver in the complex of the anionic polyester and silver was calculated as 30,480 ppm by weight. 5 Silver has a minimum inhibitory concentration (MIC) against E Coli of 10 ppm, as measured in a suitable growth medium and as described by Bhargava, H. et al in the American Journal of Infection Control, June 1996, pages 209-218. The MIC for a particular antimicrobial agent and a particular microbe is defined as the minimum concentration of that antimicrobial agent 10 that must be present in an otherwise suitable growth medium for that microbe, in order to render the growth medium unsuitable for that microbe, i.e., the minimum concentration to inhibit growth of that microbe. A demonstration of this MIC is seen in the disk diffusion method of 15 susceptibility. A filter paper disk, or other object, impregnated with a pre selected amount of a particular antimicrobial metal is applied to an agar medium that is inoculated with the test organism. The antimicrobial metal diffuses through the medium, and as long as the concentration of the antimicrobial metal is above the minimum inhibitory concentration (MIC), 20 none of the susceptible microbe will grow on or around the disk for some distance. This distance is called a zone of inhibition. Assuming the antimicrobial metal has a diffusion rate in the medium, the presence of a zone of inhibition around a disk impregnated with an antimicrobial agent indicates that the organism is inhibited by the presence of the antimicrobial 25 metal in the otherwise satisfactory growth medium, the diameter of the zone of inhibition is inversely proportional to the MIC. 30 Document2 19 The antimicrobial efficacy was evaluated by zone of inhibition assay, in which the sutures were cut into a 5 cm section. A Petri dish containing nutrient agar inoculated with about 105 cfu/m l. A portion of 20 m I of TSA tempered at 470C was added into the Petri dish. The inoculum was mixed thoroughly with 5 the growth medium and the suture was placed in the middle of the dish. The inoculated dish was incubated at 370C for 48 hr and the zone of inhibition was measured with a digital caliper. The zone of inhibition assay was performed against E coli over a two-day 10 period. The results indicate that the suture having the complex as a coating thereon exhibited a zone of inhibition against E. Coli of 4.5 mm that was sustained for 12 days. EXAMPLE 2 15 A polycaprolactone polymer containing a carboxylic acid group was prepared utilizing glycolic acid, at an initiator ratio of 30, and a catalyst in the amounts given below: epsilon-caprolactone 5000 grams 20 glycolic acid 111.048 grams catalyst: Stannous octoate 0.33 molar solution in toluene The anionic polyester had a molecular weight Mw = 6600 and an inherent viscosity in HFIP of 0.4 dl/g. 25 The anionic polyester was dissolved in ethyl acetate to make a 7% solids solution. Thereafter, a size 0 braided polyester suture was dipped into the anionic polyester/ethyl acetate solution, and the ethyl acetate was evaporated thereafter. The coating content of the suture was 2.65% by 30 weight. Document2 20 The anionic polyester coated suture was immersed in isopropanol for 10 minutes. Thereafter, it was immersed for 6 hours in a silver acetate water solution containing 0.943% silver acetate and 4.716% isopropanol. The suture was then washed with deionized water and vacuum dried to produce 5 a suture having the antimicrobial composition as a coating thereon. The amount of silver in the complex of the anionic polyester and silver was calculated as 35,200 ppm by weight. The antimicrobial efficacy was evaluated by a zone of inhibition assay as 10 described in Example 1. The zone of inhibition assay was performed against E coli over a two-day period. The results indicate that the suture having the complex as a coating thereon exhibited a zone of inhibition against E. Coli of 6.8 mm after 24 hours. 15 EXAMPLE 3 A 65/35 lactide/glycolide anionic polyester was prepared using glycolic acid initiator at a monomer to initiator mole ratio of 30. The catalyst was a 0.33 molar solution of stannous octoate in toluene. A monomer / catalyst mole ratio of 25,000 was used. 20 The reactant amounts were: L(-) lactide 1.3 moles Glycolide 0.7 moles 25 Glycolic acid 0.0666 moles Catalyst: Stannous octoate solution 0.33 molar solution of toluene A coating dispersion of the anionic polyester and calcium stearate in ethyl acetate (4.5 weight % copolymer and 4.5 weight % calcium stearate) was 30 prepared with high shear mixing. A size 2/0 uncoated polyglactin 910 suture was dip coated in the suspension and the ethyl acetate was evaporated. The coating content of the suture was 4.07% by weight. Document2 21 The anionic polyester coated suture was immersed for 5 hours in a silver acetate water solution containing 0.634% silver acetate and 12.18% isopropyl alcohol. It was washed with deionized water and vacuum dried to produce a suture having the antimicrobial composition as a coating thereon. 5 The amount of silver in the complex of the anionic polyester and silver was calculated as 27,700 ppm by weight. The antimicrobial efficacy was evaluated by a zone of inhibition assay as described in Example 1. The zone of inhibition assay was performed against 10 E coli over a two-day period. The results indicate that the suture having the complex as a coating thereon exhibited a zone of inhibition against E. Coli of 1.7 mm after 24 hours. EXAMPLE 4 15 In this example, the direct conversion of the anionic polyester to a complex of an anionic polymer with an antimicrobial metal is accomplished prior to placement on a substrate such as a medical device. Two samples were prepared, an Inventive Sample that uses the anionic 20 polyester technology of this invention and a second example that uses a non-ionic polyester of the same copolymer. Inventive Sample An anionic polyester composed of 90/10 caprolactone/glycolide was 25 synthesized by using a glycolic acid initiator at a molar ratio of monomer to initiator of 43. A film was prepared as follows: Two grams of the anionic polyester were ground and wetted with 0.3 grams of isopropanol. The solids were then admixed with a silver acetate water 30 solution, containing 0.0619 grams silver acetate in 10 grams of water. After two hours, the complex of the anionic polymer with silver was recovered by filtration and dried under vacuum at room temperature. About 1.5 grams of Document2 22 the complex was placed on a Teflon lined 0.010" mold. The mold was kept in an oven at 400C for about 10 minutes to facilitate film formation. Comparative Sample 5 A nonionic polyester composed of 90/10 caprolatone/glycolide was synthesized by using mannitol as an initiator, as described in U.S. Patent Application 2004/0153125. Silver was added as a salt dispersed into molten nonionic polyester coating and converted into a film. About 1.5 grams of the mixture was placed on a Teflon lined 0.010" mold. The mold was kept in an 10 oven at 400C for about 10 minutes to facilitate film formation. The antimicrobial efficacy was evaluated by a zone of inhibition assay, as described in Example 1 except that the films were cut into 1 sq. cm section. The zone of inhibition assay was performed against S. aureus, E. coli and 15 P.aeruginosa over a two-day period. The results are shown below. Zone of inhibition test Sample S. aureus E. coli P.aeruginosa 20 (a) 2% Ag ion exch in Cap/Gly - ++ + (b) 2% Ag based on Ag acetate in Cap/Gly - + ++ medium inhibition (small but clear zone around test article) + low inhibition (unclear clear zone around test article) 25 - No inhibition (no inhibition zone) (a) Cap/Gly initiated with Glycolic acid (Inventive Sample) (b) Cap/Gly initiated with Mannitol (Comparative Sample) Loq reduction 30 In this test, one side of the film was exposed to about 2000 CFU/ 0.5 sq. cm S. aureus in 10 ul saline with 20% serum for 60 min. The log reduction is the difference in bacteria count of test articles with or without exposure to S. aureus. This test measures the reduction of bacteria population in a short time, in no growth condition. Document2 23 Sample S. aureus (a) 2% Ag ion exch in Cap/Gly 0.5 (b) 2% Ag acetate in Cap/Gly 0 5 (a) Cap/Gly initiated with Glycolic acid (Inventive Sample) (b) Cap/Gly initiated with Mannitol (Comparative Sample) Accordingly, the data demonstrate the enhanced efficacy of the antimicrobial anionic polyester complexes of the present invention as compared to 10 antimicrobial salts dispersed in polymer matrices as a mixture. This application is a divisional of application no. 2011205306, the disclosures of which are deemed to be incorporated herein. 15 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. 20 The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that the prior art forms part of the common general knowledge. 25 Document2
Claims (20)
1. An antimicrobial composition comprising an ionic complex of an anionic polyester with an antimicrobial metal, wherein the anionic polyester 5 has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g.
2. The antimicrobial composition according to claim 1, wherein the anionic polyester has a weight average molecular weight (Mw) between about 2000 and about 7200 Daltons. 10
3. The antimicrobial composition according to claim 1, wherein the composition contains from about 20,000 ppm to about 96,000 ppm byweight of the antimicrobial metal. 15
4. The antimicrobial composition according to claim 1, wherein the anionic polyester is prepared from a ring-opening polymerization of aliphatic lactone monomers polymerized in the presence of an organometallic catalyst and an anionic initiator. 20
5. The antimicrobial composition according to claim 4, wherein the aliphatic lactone monomer is selected from the group consisting of glycolide, trimethylene carbonate, L-lactide, D-lactide, DL-lactide, mesolactide, g caprolactone, p-dioxanone, 1,3-dioxan-2-one, 5-valerolactone, p butyrolactone, E-decalactone, 2,5-diketomorpholine, pivalolactone, a,a 25 diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4 dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, y-butyrolactone, 1,4 dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl-dioxepan-2-one, 6,8 dioxabicycloctane-7-one and combinations thereof. 30 Document2 25
6. The antimicrobial composition according to claim 4, wherein the anionic initiator is selected from the group consisting of alpha-hydroxy acids, glycolic acid, D- lactic acid, DL-lactic acid, L-lactic acid, p-hydroxyacids, y hydroxyacids, 6-hydroxyacids, s-hydroxyacids, g-hydroxycaproic acid, 5 polyhydroxyacids, tartaric acid, citric acid and glucoronic acid.
7. The antimicrobial composition according to claim 4, wherein the mole ratio of lactone monomer to initiator is between about 10 and 30. 10
8. The antimicrobial composition of claim 1 wherein the antimicrobial metal is selected from the group consisting of Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, Zn, Ni, Mg, and Mn.
9. The antimicrobial composition of claim 8, wherein the antimicrobial 15 metal is silver.
10. The antimicrobial composition of claim 3, wherein the antimicrobial metal is silver. 20
11. A medical device having an antimicrobial composition comprising: an ionic complex of an anionic polyester with an antimicrobial metal wherein the anionic polyester has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g. 25
12. The medical device of according to claim 11, which is in the form of a fiber, mesh, powder, microspheres, flakes, sponge, foam, fabric, nonwoven, woven mat, a film, suture anchor device, suture, catheter, staple, surgical tack, clips, plate and screw, drug delivery device, adhesion prevention barrier, and tissue adhesive. 30
13. The medical device of according to claim 11, wherein the anionic polyester has a weight average molecular weight (Mw) between about 2000 and about 7200 Daltons. Document2 26
14. The medical device of according to claim 11, wherein the composition contains from about 20,000 ppm to about 96,000 ppm by weight of the antimicrobial metal. 5
15. A method of making an ionic complex of an anionic polyester with an antimicrobial metal comprising: conducting a ring-opening polymerization of one or more aliphatic lactone monomers in the presence of an organometallic catalyst and an anionic initiator at a mole ratio of lactone monomer to initiator between about 10 10 and 30; recovering the anionic polyester which has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g; conducting an ion exchange between carboxylic acid groups on said anionic polyester and said antimicrobial metal; and 15 recovering said ionic complex of said anionic polyester and said antimicrobial metal.
16. The method of claim 15, wherein said aliphatic lactone monomer is selected from the group consisting of glycolide, trimethylene carbonate, L 20 lactide, D-lactide, DL-lactide, mesolactide, g-caprolactone, p-dioxanone, 1,3 dioxan-2-one, 5-valerolactone, p-butyrolactone, E-decalactone, 2,5 diketomorpholine, pivalolactone, a,a-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1 ,4-dioxane-2,5-dione, 3,3-diethyl-1 4 dioxan-2,5-dione, y-butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 25 6,6-dimethyl-dioxepan-2-one, 6,8-dioxabicycloctane-7-one and combinations thereof.
17. The method of claim 15, wherein said anionic initiator is selected from the group consisting of alpha-hydroxy acids, glycolic acid, D-lactic acid, DL 30 lactic acid, L-lactic acid, p-hydroxyacids, y-hydroxyacids, 6-hydroxyacids, g hydroxyacids, g-hydroxycaproic acid, polyhydroxyacids, tartaric acid, citric acid and glucoronic acid. Document2 27
18. The method of claim 15, wherein said antimicrobial metal is selected from the group consisting of Ag, Au, Pt, Pd, Ir, Sn, Cu, Sb, Bi, Zn, Ni, Mg, and Mn. 5
19. The method of claim 15, wherein said antimicrobial metal is silver.
20. The method of claim 15, wherein the ion exchange is conducted in a solution of said antimicrobial metal in an aqueous soluble alcohol selected 10 from the group consisting of ethanol, n-propyl alcohol, and isopropyl alcohol. Document2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015258174A AU2015258174A1 (en) | 2010-01-15 | 2015-11-17 | Antimicrobial polymer compositions and the use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/688,435 | 2010-01-15 | ||
| AU2011205306A AU2011205306A1 (en) | 2010-01-15 | 2011-01-13 | Antimicrobial polymer compositions and the use thereof |
| AU2015258174A AU2015258174A1 (en) | 2010-01-15 | 2015-11-17 | Antimicrobial polymer compositions and the use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011205306A Division AU2011205306A1 (en) | 2010-01-15 | 2011-01-13 | Antimicrobial polymer compositions and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015258174A1 true AU2015258174A1 (en) | 2015-12-03 |
Family
ID=54707415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015258174A Abandoned AU2015258174A1 (en) | 2010-01-15 | 2015-11-17 | Antimicrobial polymer compositions and the use thereof |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2015258174A1 (en) |
-
2015
- 2015-11-17 AU AU2015258174A patent/AU2015258174A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9149558B2 (en) | Antimicrobial polymer compositions and the use thereof | |
| EP1881855B1 (en) | Antimicrobial polymer compositions and the use thereof | |
| US9180229B2 (en) | Antimicrobial polymer compositions and the use thereof | |
| CN102770164B (en) | Reduce the absorbable polyethylene benzilate copolymer of microorganism attachment in medical treatment device and implant | |
| US6514517B2 (en) | Antimicrobial coatings for medical devices | |
| KR101485330B1 (en) | Antimicrobial polymer compositions and the use thereof | |
| AU2015258174A1 (en) | Antimicrobial polymer compositions and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |